CPHRF (Cipher Pharmaceuticals) Tariff Resilience Score: 6/10 (As of Jul. 04, 2026)


CPHRF Cipher Pharmaceuticals Inc CPHRF
96 GF Score
Price $11.77
GF Value $12.20
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Cipher Pharmaceuticals Tariff Resilience Score?

Cipher Pharmaceuticals CPHRF 96 Tariff Resilience Score is 6 as of Jul. 04, 2026. GuruFocus rates CPHRF with a GF Score™ of 96/100 and a GF Value™ of $12.20 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Cipher Pharmaceuticals ranks better than 91.17% on this metric.

Cipher Pharmaceuticals has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Cipher Pharmaceuticals has Operates in a sector with some tariff exemptions. Global supply chain but diversified markets. Historical impacts have been moderate, with some ability to shift suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Cipher Pharmaceuticals might have Average Resilient.

Cipher Pharmaceuticals  (OTCPK:CPHRF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Cipher Pharmaceuticals Tariff Resilience Score Related Terms

CPHRF vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cipher Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Cipher Pharmaceuticals's Tariff Resilience Score falls into.


CPHRF
96GF Score
Cipher Pharmaceuticals Inc CPHRF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Cipher Pharmaceuticals (CPHRF) has a Tariff Resilience Score of 6 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Cipher Pharmaceuticals ranks #91 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is Cipher Pharmaceuticals' Tariff Resilience Score too high?
Cipher Pharmaceuticals' current Tariff Resilience Score is 6. Based on the distribution chart, Cipher Pharmaceuticals ranks #91 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cipher Pharmaceuticals has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipher Pharmaceuticals ranks #91 out of 1030 companies for Tariff Resilience Score. This places Cipher Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Cipher Pharmaceuticals's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (CPHRF) is currently considered Fairly Valued. The stock's GF Value™ is $12.20, compared to a current price of $11.77 — trading 3.6% below its estimated fair value. The current Tariff Resilience Score is 6. Cipher Pharmaceuticals' overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Cipher Pharmaceuticals (CPHRF), the current Tariff Resilience Score is 6 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipher Pharmaceuticals (CPHRF) Overvalued in 2026?

Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued. The current stock price of $11.77 is trading 3.6% below its estimated GF Value™ of $12.20. GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.

Key valuation signals for CPHRF:

  • Tariff Resilience Score: 6
  • GF Value™: $12.20 vs. price of $11.77 (3.6% below fair value)
  • GF Score™: 96/100 with 5 warning signs

No single metric tells the full story. See the CPHRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipher Pharmaceuticals Business Description

Other Exchanges PHE:GermanyCPH:Canada
Address 5750 Explorer Drive, Suite 404, Mississauga, ON, CAN, L4W 0A9
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
96GF Score

Get the complete analysis for CPHRF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.77
Price
$12.20
GF Value